On August 6, 10x Genomics (NASDAQ:TXG) reported second-quarter revenue of $151 million, boosted by a $1.6 million settlement payment from Takara. Strip that out and revenue grew just 3% year-over-year to $149.4 million, a modest number next to the real headline of the quarter: a brand-new instrument platform called Atera, where booked orders have exceeded […]

10x Genomics (TXG) has drawn fresh investor attention after raising its 2026 revenue outlook on 6 August, citing strong early orders for its new Atera platform and ongoing integration of Proteintech Genomics. See our latest analysis for 10x Genomics. The market reaction around 10x Genomics’ updated 2026 outlook and Atera launch has been choppy, with a 1-day share price return that declined 3.54%, yet shorter term momentum remains strong given a 30-day share price return of 28.23% and a 90-day...

10x Genomics’ second quarter results came in above Wall Street’s expectations for both revenue and profitability, yet the market responded negatively. Management attributed the year-over-year revenue decline to lower instrument sales, particularly as customers moderated purchases of current spatial products in anticipation of the upcoming Atera platform. CEO Serge Saxonov emphasized the strong momentum in Chromium consumables and growing engagement across both academic and biopharma customers, w

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.

Atera demand drives spatial transition as booked orders exceed 2026 targets.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Biotech company 10x Genomics (NASDAQ:TXG) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 12.6% year on year to $151 million. The company’s full-year revenue guidance of $620 million at the midpoint came in 1% above analysts’ estimates. Its GAAP loss of $0.14 per share was 44.2% above analysts’ consensus estimates.

10x Genomics (NASDAQ:TXG) reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara. Excluding non-recurring settlement revenue in both periods, revenue was $149.4 million, up 3% from a year earlier. Chief Executive Off

TXG beats Q2 earnings and revenue estimates, expands gross margin and raises its 2026 revenue outlook despite a year-over-year sales decline.

Moby summary of 10x Genomics, Inc.'s Q2 2026 earnings call

Biotech company 10x Genomics (NASDAQ:TXG) reported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 12.6% year on year to $151 million. The company’s full-year revenue guidance of $620 million at the midpoint came in 1% above analysts’ estimates. Its GAAP loss of $0.14 per share was 43.3% above analysts’ consensus estimates.

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

10x Genomics (TXG) delivered earnings and revenue surprises of +39.13% and +2.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10x Genomics (NasdaqGS:TXG) announced a multi year research collaboration with Lausanne University Hospital focused on cancer diagnostics using single cell and spatial technologies. The partnership aims to generate clinically actionable biomarkers and integrate them directly into cancer care workflows. The collaboration will use large scale patient data to explore more personalized treatment options in oncology. 10x Genomics enters this collaboration with Lausanne University Hospital as a...

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 14.3% over the past six months while the S&P 500 was up 6.3%.

A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance patients have, in this case, an increase in uninsured individuals resulting from losses in health insurance exchange coverage. For HCA, this shift was significant, reducing pre-tax income by an estimated $400 million

Cathie Wood Trims AMD to Fund Bigger SpaceX Bet

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.

ARK's purchases come as investors closely watch progress on U.S. crypto legislation, including the CLARITY Act and stablecoin regulation efforts.

Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.

Cathie Wood Unveils Major Portfolio Reset With SpaceX, Meta Buys and AMD Cuts